Literature DB >> 22158723

An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis.

Vijay Kumar Prajapati1, Kalpna Awasthi, Thakur Prasad Yadav, Madhukar Rai, Onkar Nath Srivastava, Shyam Sundar.   

Abstract

Amphotericin B (AmB), is a highly effective antileishmanial agent used as first-line treatment in different formulations in visceral leishmaniasis endemic areas of Bihar, India. However, parenteral infusion, prolonged hospitalization, and toxicity are major hurdles. Our previous work demonstrated the efficacy and stability of functionalized carbon nanotubes as a delivery mechanism for AmB. In this study, using the hamster model, we have shown that this novel formulation of AmB can be administered orally, resulting in 99% inhibition of parasite growth following a 5-day course at 15 mg/kg body weight.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22158723      PMCID: PMC3244370          DOI: 10.1093/infdis/jir735

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Noncovalent sidewall functionalization of single-walled carbon nanotubes for protein immobilization.

Authors:  R J Chen; Y Zhang; D Wang; H Dai
Journal:  J Am Chem Soc       Date:  2001-04-25       Impact factor: 15.419

2.  Translocation of bioactive peptides across cell membranes by carbon nanotubes.

Authors:  Davide Pantarotto; Jean-Paul Briand; Maurizio Prato; Alberto Bianco
Journal:  Chem Commun (Camb)       Date:  2003-11-03       Impact factor: 6.222

3.  Evaluation of blood agar microtiter plates for culturing leishmania parasites to titrate parasite burden in spleen and peripheral blood of patients with visceral leishmaniasis.

Authors:  Radheshyam Maurya; Sanjana Mehrotra; Vijay Kumar Prajapati; Susanne Nylén; David Sacks; Shyam Sundar
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

4.  Antileishmanial activity of nano-amphotericin B deoxycholate.

Authors:  Krishna Das Manandhar; Thakur Prasad Yadav; Vijay Kumar Prajapati; Subodh Kumar; Madhukar Rai; Anuradha Dube; Onkar Nath Srivastava; Shyam Sundar
Journal:  J Antimicrob Chemother       Date:  2008-05-02       Impact factor: 5.790

5.  Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases.

Authors:  C P Thakur; R K Singh; S M Hassan; R Kumar; S Narain; A Kumar
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 May-Jun       Impact factor: 2.184

6.  Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes.

Authors:  Vijay Kumar Prajapati; Kalpana Awasthi; Shalini Gautam; Thakur Prasad Yadav; Madhukar Rai; Onkar Nath Srivastava; Shyam Sundar
Journal:  J Antimicrob Chemother       Date:  2011-02-03       Impact factor: 5.790

7.  The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India.

Authors:  M Boelaert; F Meheus; A Sanchez; S P Singh; V Vanlerberghe; A Picado; B Meessen; S Sundar
Journal:  Trop Med Int Health       Date:  2009-04-20       Impact factor: 2.622

Review 8.  New formulations and derivatives of amphotericin B for treatment of leishmaniasis.

Authors:  J Golenser; A Domb
Journal:  Mini Rev Med Chem       Date:  2006-02       Impact factor: 3.862

Review 9.  Functionalized carbon nanotubes in drug design and discovery.

Authors:  Maurizio Prato; Kostas Kostarelos; Alberto Bianco
Journal:  Acc Chem Res       Date:  2007-09-15       Impact factor: 22.384

10.  Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.

Authors:  Kishor M Wasan; Ellen K Wasan; Pavel Gershkovich; Xiaohua Zhu; Richard R Tidwell; Karl A Werbovetz; John G Clement; Sheila J Thornton
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226

View more
  23 in total

Review 1.  Oral bioavailability: issues and solutions via nanoformulations.

Authors:  Kamla Pathak; Smita Raghuvanshi
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

Review 2.  Recent developments and future prospects in the treatment of visceral leishmaniasis.

Authors:  Shyam Sundar; Anup Singh
Journal:  Ther Adv Infect Dis       Date:  2016-04-22

3.  Solute carrier protein family 11 member 1 (Slc11a1) activation efficiently inhibits Leishmania donovani survival in host macrophages.

Authors:  Nisha Singh; Mallikarjuna Rao Gedda; Neeraj Tiwari; Suya P Singh; Surabhi Bajpai; Rakesh K Singh
Journal:  J Parasit Dis       Date:  2016-11-12

4.  Investigational drugs for visceral leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Investig Drugs       Date:  2014-11-20       Impact factor: 6.206

Review 5.  Plant-derived compounds in treatment of leishmaniasis.

Authors:  A Oryan
Journal:  Iran J Vet Res       Date:  2015       Impact factor: 1.376

Review 6.  Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application.

Authors:  Om Prakash Singh; Mallikarjuna Rao Gedda; Shyam Lal Mudavath; Onkar Nath Srivastava; Shyam Sundar
Journal:  Nanomedicine (Lond)       Date:  2019-07-17       Impact factor: 5.307

7.  Safety, Tolerability, and Pharmacokinetics of a Novel Oral Amphotericin B Formulation (iCo-019) following Single-Dose Administration to Healthy Human Subjects: an Alternative Approach to Parenteral Amphotericin B Administration.

Authors:  Peter Hnik; Ellen K Wasan; Kishor M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

8.  Assessing the Safety, Tolerability, Pharmacokinetics, and Biodistribution of Novel Oral Formulations of Amphotericin B following Single- and Multiple-Dose Administration to Beagle Dogs.

Authors:  Kishor M Wasan; Ellen K Wasan; Peter Hnik
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

9.  Nanoparticle toxicity by the gastrointestinal route: evidence and knowledge gaps.

Authors:  Ingrid L Bergin; Frank A Witzmann
Journal:  Int J Biomed Nanosci Nanotechnol       Date:  2013

10.  Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats.

Authors:  Mahasen A Radwan; Bushra T AlQuadeib; Lidija Šiller; Matthew C Wright; Benjamin Horrocks
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.